3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Sarcoma
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Mouth Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Cyclophosphamide
7
pembrolizumab
6
fludarabine
6
aldesleukin
4
fludarabine phosphate
2
entinostat
2
Trastuzumab
2
Radiotherapy
2
Psychiatric Rehabilitation
2
Nivolumab
2
Interleukin-2
2
Interleukin-12 Subunit p35
2
Early Intervention, Educational
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
tislelizumab
1
tipifarnib
1
spartalizumab
1
rocakinogene sifuplasmid
1
oncogene protein E7, Human papillomavirus type 16
1
enzalutamide
1
durvalumab
1
cemiplimab
1
bintrafusp alfa protein, human
1
atezolizumab
1
alovudine
1
abiraterone
1
Vorinostat
1
Vaccines, Synthetic
1
VGX-3100
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anus Neoplasms
×
trastuzumab deruxtecan
×
Genitourinary
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled